News

Omnaris HFA is an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. Ciclesonide is the active ingredient in

Sanofi-aventis is initially expected to produce oral antidiabetic and cardiovascular products in the new plant which is to be build in 35,000 square meter land. The agreement was

Cubist said that CXA-201, a combined product of CXA-101 and the beta-lactamase inhibitor tazobactam, is being developed by the company as a first-line intravenous therapy for the treatment

Thermo Fisher Scientific said that the new library has been computationally engineered to build on the customer-driven features of the original Maybridge Ro3 Library, such as ‘Rule of

As per the terms of the licensing and supply agreement, ULURU is expected to get an upfront licensing payment, milestone payments based on regulatory approvals and sales performance

To identify selectively interacting proteins of a drug molecule, it is coupled to caprotec’s Capture Compound scaffold and incubated with human cell lysates, subcellular fractions or whole cells.

Remoxy, being developed by King Pharmaceuticals, is a painkiller with a formulation designed to reduce potential risks of unintended use. Apart from this drug, King Pharmaceuticals is also

As per the terms of the agreement GSK is expected to fully fund and be responsible for all clinical and regulatory development. Additionally, GSK is also expected to

Merck said that the Louisiana case is the first Vioxx lawsuit brought by a state attorney general to go to trial. The case was filed by the Louisiana